The DOI matches its Crossref record; 145 of the 145 references it cites were found in a registry or an index.
Levetiracetam and brivaracetam: a review of evidence from clinical trials and clinical experience
Open accessAbstract
Until the early 1990s, a limited number of antiepileptic drugs (AEDs) were available. Since then, a large variety of new AEDs have been developed and introduced, several of them offering new modes of action. One of these new AED families is described and reviewed in this article. Levetiracetam (LEV) and brivaracetam (BRV) are pyrrolidone derivate compounds binding at the presynaptic SV2A receptor site and are thus representative of AEDs with a unique mode of action. LEV was extensively investigated in randomized controlled trials and has a very promising efficacy both in focal and generalized epilepsies. Its pharmacokinetic profile is favorable and LEV does not undergo clinically relevant interactions. Adverse reactions comprise mainly asthenia, somnolence, and behavioral symptoms. It has now been established as a first-line antiepileptic drug. BRV has been recently introduced as an adjunct antiepileptic drug in focal epilepsy with a similarly promising pharmacokinetic profile and possibly increased tolerability concerning psychiatric adverse events. This review summarizes the essential preclinical and clinical data of LEV and BRV that is currently available and includes the experiences at a large tertiary referral epilepsy center.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Clinically, both levetiracetam and brivaracetam have favorable safety, simple kinetics, and flexible dosing that support long-term administration [224,225].”
From Synaptic Plasticity—Intrinsic Excitability and Antidepressant Discovery (2026) · cites this paper as [225]
The cited source says what the claim attributes to it.
In the citing paper
“Brivaracetam may show improved behavioral tolerability in some patients, and switching within the class is feasible when adverse effects emerge, enabling continuity of presynaptic stabilization [219,225].”
From Synaptic Plasticity—Intrinsic Excitability and Antidepressant Discovery (2026) · cites this paper as [225]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam
Lynch, B. A., Lambeng, N., Nocka, K., Kensel-Hammes, P., Bajjalieh, S. M., Matagne, A., & Fuks, B. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0308208101 · Cited by 1,610
Jasper's Basic Mechanisms of the Epilepsies
(2012) · Oxford University Press eBooks · doi:10.1093/med/9780199746545.001.0001 · Cited by 1,143
Antiepileptic Drug Mechanisms of Action
Macdonald, R. L., & Kelly, K. M. (1995) · Epilepsia · doi:10.1111/j.1528-1157.1995.tb05996.x · Cited by 591
Tomson, T., Battino, D., Bonizzoni, E., Craig, J., Lindhout, D., Perucca, E., Sabers, A., Thomas, S. V., Vajda, F., Faravelli, F., et al. (2018) · The Lancet Neurology · doi:10.1016/s1474-4422(18)30107-8 · Cited by 544
Levetiracetam for partial seizures: Results of a double-blind, randomized clinical trial
Cereghino, J. J., Biton, V., Abou-Khalil, B., Dreifuss, F., Gauer, L. J., Leppik, I., & the United States Levetiracetam Study Group (2000) · Neurology · doi:10.1212/wnl.55.2.236 · Cited by 524
Pharmacokinetic profile of levetiracetam
Patsalos, P. N. (2000) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(99)00052-2 · Cited by 519
Evidence for a unique profile of levetiracetam in rodent models of seizures and epilepsy
Klitgaard, H., Matagne, A., Gobert, J., & Wülfert, E. (1998) · European Journal of Pharmacology · doi:10.1016/s0014-2999(98)00410-5 · Cited by 506
Clinical Pharmacokinetics of Levetiracetam
Patsalos, P. N. (2004) · Clinical Pharmacokinetics · doi:10.2165/00003088-200443110-00002 · Cited by 473
Comparison of levetiracetam and controlled-release carbamazepine in newly diagnosed epilepsy
Brodie, M. J., Perucca, E., Ryvlin, P., Ben-Menachem, E., & Meencke, H.-J. (2007) · Neurology · doi:10.1212/01.wnl.0000252941.50833.4a · Cited by 467
Shorvon, S. D., Löwenthal, A., Janz, D., Bielen, E., Loiseau, P., & for the European Levetiracetam Study Group (2000) · Epilepsia · doi:10.1111/j.1528-1157.2000.tb00323.x · Cited by 451
Research works printed but not linked: 13
- 10.1111/j.1527-3458.2005.tb00268.x · DOI · Paper page
- De Smedt T, 2007, et al., 13, 57
- Ulloa CM, 2009, Neuropsychiatr Dis Treat, 5, 467
- Perucca E, 2000, Epilepsia, 41, 150
- Klein P, 2018, Clin Pharmacol, 10, 1
- Hannestad J, 2016, Epilepsia, 57, 128
- Lacroix B, 2007, Epilepsia, 48, 333
- Otoul C, 2015, Poster presented at American Epilepsy Society 69th Annual meeting
- Detrait E, 2008, Epilepsia, 49
- Werhahn KJ, Epilepsia, 6, 450
- 10.1016/j.eplepsyres.2007.06.002 · DOI
- Buck ML., 2002, Pediatric Pharmacoth, 8, 1
- D’Souza J, 2012, Epilepsia, 53, P402
Cited by
Levetiracetam Mechanisms of Action: From Molecules to Systems
Contreras-García, I. J., Cárdenas-Rodríguez, N., Romo-Mancillas, A., Bandala, C., Zamudio, S. R., Gómez-Manzo, S., Hernández-Ochoa, B., Mendoza-Torreblanca, J. G., & Pichardo-Macías, L. A. (2022) · Pharmaceuticals · doi:10.3390/ph15040475 · Cited by 131
Towards Realizing the Vision of Precision Medicine: AI Based Prediction of Clinical Drug Response
de Jong, J., Cutcutache, I., Page, M., Elmoufti, S., Dilley, C., Fröhlich, H., & Armstrong, M. (2020) · Brain · doi:10.1093/brain/awab108 · Cited by 115
The pharmacological treatment of epilepsy: recent advances and future perspectives
Perucca, E. (2021) · Acta Epileptologica · doi:10.1186/s42494-021-00055-z · Cited by 110
Palliative care and end-of-life care in adults with malignant brain tumors
Koekkoek, J. A. F., van der Meer, P. B., Pace, A., Hertler, C., Harrison, R. A., Leeper, H. E., Forst, D. A., Jalali, R., Oliver, K. R., Philip, J. A. M., et al. (2022) · Neuro-Oncology · doi:10.1093/neuonc/noac216 · Cited by 103
Neurocognitive Effects of Antiseizure Medications in Children and Adolescents with Epilepsy
Besag, F., & Vasey, M. J. (2021) · Pediatric Drugs · doi:10.1007/s40272-021-00448-0 · Cited by 93
Metadata
- Authors
- Steinhoff, B. J., & Staack, A. M.
- Affiliations
- Diakonie Kork (DE)
- Corresponding author
- Steinhoff, Bernhard J.
- Venue
- Therapeutic Advances in Neurological Disorders
- Publisher
- SAGE Publications
- Published
- 2019-01
- Volume
- 12
- Pages
- 1756286419873518-1756286419873518
- ISSN
- 1756-2856 (ISSN-L)
- 1756-2864
- PMC
- PMC6734620
- OpenAlex
- W2973225802
- Semantic Scholar
- bdff5b0eebcdf5f0c63ceceb24eab6399dc13cbf
- Cited by
- 99
- References
- 144
- Citations by year
- 2026: 17 · 2025: 9 · 2024: 17 · 2023: 12 · 2022: 15 · 2021: 19 · 2020: 8 · 2019: 1
- FWCI
- 1.82
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by-nc
- journals.sagepub.com/page/policies/text-and-data-mining-license (tdm)
- Locations
- Therapeutic Advances in Neurological Disorders (publishedVersion, cc-by-nc)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Health Sciences › Medicine › Clinical Neurology › Epilepsy research and treatment
- Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Pharmacological Effects and Toxicity Studies
- Health Sciences › Medicine › Physiology (medical) › Diet and metabolism studies
- Keywords
- levetiracetam, brivaracetam, antiepileptic drugs, pyrrolidinone derivatives, focal epilepsy, generalized epilepsy, pharmacokinetics, drug interactions, adverse drug reactions, adjunctive therapy, first-line therapy, epilepsy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Levetiracetam and brivaracetam: a review of evidence from clinical trials and clinical experience. https://app.cochat.ai/papers/10.1177/1756286419873518
- The paper
- Steinhoff, B. J., & Staack, A. M. (2019). Levetiracetam and brivaracetam: a review of evidence from clinical trials and clinical experience. Therapeutic Advances in Neurological Disorders. https://doi.org/10.1177/1756286419873518
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.